Send us a Message
Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Search RGD Grant Resources Citing RGD About Us Contact Us
Genes Variants Community Projects QTLs Strains Markers Genome Information Ontologies Cell Lines References Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Synteny Browser (VCMap) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) AllianceMine GViewer (Genome Viewer)
Aging & Age-Related Disease Cancer & Neoplastic Disease Cardiovascular Disease Coronavirus Disease Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Infectious Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models Genetic Models Autism Models Rat PhenoMiner (Quantitative Phenotypes) Chinchilla PhenoMiner Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Presentations Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources
Advanced Search (OLGA)

Ontology Browser
Term:
Parent Terms Term With Siblings Child Terms
anti-estrogen drug pathway +     
axitinib drug pathway +     
bortezomib drug pathway +  
capecitabine drug pathway +   
cyclophosphamide drug pathway +   
docetaxel drug pathway +   
doxorubicin drug pathway +     
erlotinib drug pathway +   
The pharmacokinetics and pharmacodynamics pathway of erlotinib. Erlotinib is the second (after gefitinib) selective inhibitor of EGFR whose mutations within the tyrosine kinase domain have been associated with hyperactive epidermal growth factor signaling in non-small cell lung cancers. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
etoposide drug pathway +   
everolimus drug pathway +  
gefitinib drug pathway +     
gemcitabine pathway +   
ifosfamide drug pathway +   
irinotecan drug pathway +   
mercaptopurine drug pathway +   
methotrexate drug pathway +   
monoclonal antibody drug pathway +   
pazopanib drug pathway +  
pemetrexed drug pathway +  
platinum (Pt) containing drug pathway +    
plevitrexed drug pathway +  
pralatrexate drug pathway +  
sorafenib drug pathway +   
sunitinib drug pathway +  
temsirolimus drug pathway +  
teniposide drug pathway +   
tioguanine drug pathway +   
vinca alkaloid drug pathway +   

Synonyms
Definition Sources: PMID:19657272, PMID:20072828

paths to the root